IAVI S001
Status:Completed
Phase:I
Principal Investigator(s):
Objective:The purpose is to evaluate the safety, tolerability and immunogenicity of Sendai HIV vaccine in prime-boost regimens in HIV-uninfected, healthy adult volunteers.
Prevention Option(s):HIV Vaccine
Study Design:Controlled, Double-blind, Randomized
Arms and Assigned Interventions
DescriptionSendai HIV vaccine SeV-G(NP) at 2x10^7 CIU at Month 0 followed by Ad35-GRIN (IM) at 1x10^10 vp at Month 4. (Vaccine/Placebo = 12/4)
Mode of DeliveryIntramuscular
ARMsExperimental
DescriptionSendai HIV vaccine SeV-G(NP) at 2x10^8 CIU at Month 0 followed by Ad35-GRIN (IM) at 1x10^10 vp at Month 4. (Vaccine/Placebo = 12/4)
Mode of DeliveryIntramuscular
ARMsExperimental
DescriptionAd35-GRIN (IM) at 1x10^10 vp at Month 0 followed by SeV-G(NP) (IN) at 2x10^8 CIU at Month 4. (Vaccine/Placebo = 12/4)
Mode of DeliveryIntramuscular
ARMsExperimental
Official Code:
NCT01705990
Trial Sponsors:
IAVI
Start Date
End Date
March 31, 2013
May 31, 2014
Enrollment:64
Age range:
18 Years ↔
50 Years
Population: